Molecular Epidemiology and Patient Outcome of Carbapenem-resistant and in Japan: a Multicenter Study from MultiDrug-Resistant Organisms Clinical Research Network

Overview

Journal JAC Antimicrob Resist

Publisher Oxford University Press

Specialty Infectious Diseases

Date 2025 Mar 7

PMID 40051884

Authors

Sho Saito

Aki Sakurai

Yasufumi Matsumura

Kohei Uemura

Ryota Hase

Hideaki Kato

Naoya Itoh

Takehiro Hashimoto

Takashi Matono

Jiefu Yu

Kayoko Hayakawa

Masahiro Suzuki

Shoki Izumi

Tetsuya Suzuki

Mari Kurokawa

Koh Shinohara

Keiichiro Mori

Yasunobu Endo

Haruki Mito

Kayoko Sano

Tomo Matsunaga

Nana Akazawa

Kazufumi Hiramatsu

Yusuke Asai

Shinya Tsuzuki

David van Duin

Norio Ohmagari

Yohei Doi

Affiliations

Soon will be listed here.

Abstract

Background And Objectives: Carbapenem-resistant Gram-negative bacilli (CRGNB), especially and , are critical pathogens associated with excess morbidity and mortality. To elucidate their molecular epidemiology and clinical outcomes in Japan, patients with CRGNB were enrolled in the MDR organisms clinical research network (MDRnet) consisting of eight tertiary care facilities.

Methods: Between 2019 and 2022, 246 unique patients with carbapenem-resistant (CRE), carbapenem-resistant (CRPA) and carbapenem-resistant (CRAB) isolates were prospectively enrolled.

Results: A total of 246 isolates were collected from 246 patients, including 78 (31.7%) CRE, 167 (67.9%) CRPA and 1 (0.4%) CRAB. For CRE, 74.4% of the isolates carried carbapenemase genes with predominance of (64.1%). Only 2.4% of CRPA had carbapenemase genes, which was lower than CRE. Among the infected patients, 20.0% and 12.5% died of CRE and CRPA within 30 days, respectively. In patients with CRE, the mortality rate within 30 days for those without carbapenemase-producing (CPE) was higher compared with those with CPE (22.2% compared with 18.8%).

Conclusions: Our study highlights the unique molecular epidemiology and clinical outcomes of CRGNB in Japan.

References

Logan L, Weinstein R . The Epidemiology of Carbapenem-Resistant Enterobacteriaceae: The Impact and Evolution of a Global Menace. J Infect Dis. 2017; 215(suppl_1):S28-S36. PMC: 5853342. DOI: 10.1093/infdis/jiw282. View

Howard-Anderson J, Earley M, Komarow L, Abbo L, Anderson D, Gallagher J . Poor outcomes in both infection and colonization with carbapenem-resistant Enterobacterales. Infect Control Hosp Epidemiol. 2022; 43(12):1840-1846. PMC: 9343470. DOI: 10.1017/ice.2022.4. View

Rahman M, Kumar Shukla S, Prasad K, Ovejero C, Pati B, Tripathi A . Prevalence and molecular characterisation of New Delhi metallo-β-lactamases NDM-1, NDM-5, NDM-6 and NDM-7 in multidrug-resistant Enterobacteriaceae from India. Int J Antimicrob Agents. 2014; 44(1):30-7. DOI: 10.1016/j.ijantimicag.2014.03.003. View

van Duin D, Perez F, Rudin S, Cober E, Hanrahan J, Ziegler J . Surveillance of carbapenem-resistant Klebsiella pneumoniae: tracking molecular epidemiology and outcomes through a regional network. Antimicrob Agents Chemother. 2014; 58(7):4035-41. PMC: 4068524. DOI: 10.1128/AAC.02636-14. View

Hara Y, Iguchi M, Tetsuka N, Morioka H, Hirabayashi A, Suzuki M . ＜Editors' Choice＞ Multicenter survey for carbapenemase-producing Enterobacterales in central Japan. Nagoya J Med Sci. 2022; 84(3):630-639. PMC: 9529634. DOI: 10.18999/nagjms.84.3.630. View

Henderson H, Luterbach C, Cober E, Richter S, Salata R, Kalayjian R . The Pitt Bacteremia Score Predicts Mortality in Nonbacteremic Infections. Clin Infect Dis. 2019; 70(9):1826-1833. PMC: 7156778. DOI: 10.1093/cid/ciz528. View

Cai B, Echols R, Magee G, Ferreira J, Morgan G, Ariyasu M . Prevalence of Carbapenem-Resistant Gram-Negative Infections in the United States Predominated by and . Open Forum Infect Dis. 2017; 4(3):ofx176. PMC: 5629822. DOI: 10.1093/ofid/ofx176. View

Pena C, Suarez C, Gozalo M, Murillas J, Almirante B, Pomar V . Prospective multicenter study of the impact of carbapenem resistance on mortality in Pseudomonas aeruginosa bloodstream infections. Antimicrob Agents Chemother. 2011; 56(3):1265-72. PMC: 3294876. DOI: 10.1128/AAC.05991-11. View

Bertrand X, Dowzicky M . Antimicrobial susceptibility among gram-negative isolates collected from intensive care units in North America, Europe, the Asia-Pacific Rim, Latin America, the Middle East, and Africa between 2004 and 2009 as part of the Tigecycline Evaluation and.... Clin Ther. 2011; 34(1):124-37. DOI: 10.1016/j.clinthera.2011.11.023. View

10.

Tamma P, Goodman K, Harris A, Tekle T, Roberts A, Taiwo A . Comparing the Outcomes of Patients With Carbapenemase-Producing and Non-Carbapenemase-Producing Carbapenem-Resistant Enterobacteriaceae Bacteremia. Clin Infect Dis. 2016; 64(3):257-264. PMC: 5241781. DOI: 10.1093/cid/ciw741. View

11.

Feldgarden M, Brover V, Gonzalez-Escalona N, Frye J, Haendiges J, Haft D . AMRFinderPlus and the Reference Gene Catalog facilitate examination of the genomic links among antimicrobial resistance, stress response, and virulence. Sci Rep. 2021; 11(1):12728. PMC: 8208984. DOI: 10.1038/s41598-021-91456-0. View

12.

van Duin D, Doi Y . The global epidemiology of carbapenemase-producing Enterobacteriaceae. Virulence. 2016; 8(4):460-469. PMC: 5477705. DOI: 10.1080/21505594.2016.1222343. View

13.

Nakayama R, Inoue-Tsuda M, Matsui H, Ito T, Hanaki H . Classification of the metallo β-lactamase subtype produced by the carbapenem-resistant Pseudomonas aeruginosa isolates in Japan. J Infect Chemother. 2021; 28(2):170-175. DOI: 10.1016/j.jiac.2021.04.005. View

14.

Hsu L, Apisarnthanarak A, Khan E, Suwantarat N, Ghafur A, Tambyah P . Carbapenem-Resistant Acinetobacter baumannii and Enterobacteriaceae in South and Southeast Asia. Clin Microbiol Rev. 2016; 30(1):1-22. PMC: 5217790. DOI: 10.1128/CMR.masthead.30-1. View

15.

Buehrle D, Shields R, Clarke L, Potoski B, Clancy C, Nguyen M . Carbapenem-Resistant Pseudomonas aeruginosa Bacteremia: Risk Factors for Mortality and Microbiologic Treatment Failure. Antimicrob Agents Chemother. 2016; 61(1). PMC: 5192105. DOI: 10.1128/AAC.01243-16. View

16.

Akeda Y . Current situation of carbapenem-resistant Enterobacteriaceae and Acinetobacter in Japan and Southeast Asia. Microbiol Immunol. 2021; 65(6):229-237. DOI: 10.1111/1348-0421.12887. View

17.

Matsui M, Suzuki M, Suzuki M, Yatsuyanagi J, Watahiki M, Hiraki Y . Distribution and Molecular Characterization of Acinetobacter baumannii International Clone II Lineage in Japan. Antimicrob Agents Chemother. 2017; 62(2). PMC: 5786803. DOI: 10.1128/AAC.02190-17. View

18.

Hayakawa K, Nakano R, Hase R, Shimatani M, Kato H, Hasumi J . Comparison between IMP carbapenemase-producing Enterobacteriaceae and non-carbapenemase-producing Enterobacteriaceae: a multicentre prospective study of the clinical and molecular epidemiology of carbapenem-resistant Enterobacteriaceae. J Antimicrob Chemother. 2019; 75(3):697-708. DOI: 10.1093/jac/dkz501. View

19.

Magiorakos A, Srinivasan A, Carey R, Carmeli Y, Falagas M, Giske C . Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect. 2011; 18(3):268-81. DOI: 10.1111/j.1469-0691.2011.03570.x. View

20.

Charlson M, Pompei P, Ales K, MacKenzie C . A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987; 40(5):373-83. DOI: 10.1016/0021-9681(87)90171-8. View